Synta Announces Results on Ganetespib Across a Range of Malignancies at the ... MarketWatch (press release) In an effort to maximize antitumor activity ganetespib was further combined with PI3K/mTOR inhibitors. As single agents, ganetespib effectively blocked both ERK and AKT/mTOR signaling; by contrast, PI3K/mTOR inhibitors blocked their targets while ... |
